<DOC>
	<DOCNO>NCT00626197</DOCNO>
	<brief_summary>This Phase III , randomize , double-blind , placebo-controlled , multicentre , parallel-group study design evaluate efficacy safety ocrelizumab add SOC ( corticosteroid plus one two immunosuppressant regimen ) compare placebo add SOC patient WHO ISN Class III IV lupus nephritis .</brief_summary>
	<brief_title>A Study Evaluate Ocrelizumab Patients With Nephritis Due Systemic Lupus Erythematosus ( BELONG )</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<mesh_term>Nephritis</mesh_term>
	<mesh_term>Lupus Nephritis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>Age 16 year time screen Ability willingness provide write informed consent comply schedule protocol requirement Diagnosis SLE Active lupus nephritis Currently active retinitis , poorly control seizure disorder , acute confusional state , myelitis , stroke stroke syndrome , cerebellar ataxia , dementia Severe renal impairment Lack peripheral venous access Pregnancy breast feed mother History severe allergic anaphylactic reaction humanize , chimeric murine monoclonal antibody i.v . immunoglobulin Known severe chronic pulmonary disease Evidence significant uncontrolled concomitant disease organ system related SLE , , investigator 's opinion , would preclude patient participation Concomitant condition require treatment systemic corticosteroid ( exclude topical inhale steroid ) prior screen Known HIV chronic active Hepatitis B chronic active Hepatitis C infection Known active infection kind prior Day 1 History serious recurrent chronic infection History cancer , include solid tumor , hematological malignancy carcinoma situ ( except basal cell carcinoma skin excise cure ) . History alcohol drug abuse prior screen Major surgery prior screening , exclude diagnostic surgery Previous treatment CAMPATH1H Previous treatment BAFF direct treatment ( e.g . antiBLyS ) prior screen Previous treatment Bcell target therapy one direct BAFF ( e.g . antiCD20 , antiCD22 ) Treatment investigational agent prior screen Receipt live vaccine prior Day 1 Intolerance contraindication oral i.v . corticosteroid Positive hepatitis BsAg hepatitis C serology . Patients HBsAg negative HBcAb positive may enrol negative DNA test</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>SLE</keyword>
	<keyword>Lupus</keyword>
	<keyword>BELONG</keyword>
</DOC>